Publicou 6 edições por ano
ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472
Indexed in
Immunogenicity of Dendritic-Tumor Fusion Hybrids and Their Utility in Cancer Immunotherapy
RESUMO
Cancer immunotherapy using fusion hybrid cells generated from dendritic cells (DCs) and tumor cells may be more effective than other DC−based vaccines. DC−tumor fusion potentially confers not only the DCs' antigen-presenting functionality but also a continuing source of endogenous tumor antigens for major-histocompatibility-complex-restricted T−cell sensitization. In animal models, many investigators demonstrated that vaccination with fusion hybrids was protective against tumor challenge and therapeutic, resulting in the regression of established tumors. In clinical trials for patients with a variety of metastatic diseases, fusion hybrid vaccines were well tolerated, but the overall objective response rate was only 10.9%. Careful scrutiny of a large number of publications revealed that, in most cases, no definitive evidence of heterokaryonic fusion cell formation was found. Further corroboration of this conclusion comes from reports that fusion hybrids generated from autologous (syngeneic) and allogeneic DCs displayed equivalent immunological function and therapeutic effects in vitro and in vivo. This puzzling finding suggests that effective fusion immunotherapy depends on tumor antigen scavenging and presentation by antigen-presenting cells (APCs) of host origin and is in violation of the basic tenet of the principle of DC function. We believe that conclusions drawn from reported clinical trials have not properly evaluated the efficacy of the DC−tumor hybrid vaccine, and therefore, they neither confirm nor disclaim the potential benefits that may be derived from this form of immunotherapy.
-
Díaz Martín D., Prieto Martín A., Monserrat Sanz J., Sánchez Luengo M.Á., Álvarez-Mon Soto M., Sistema inmune y cáncer, Medicine - Programa de Formación Médica Continuada Acreditado, 10, 28, 2009. Crossref
-
Tan Chunrui, Dannull Jens, Nair Smita K., Ding Enyu, Tyler Douglas S., Pruitt Scott K., Lee Walter T., Local secretion of IL-12 augments the therapeutic impact of dendritic cell–tumor cell fusion vaccination, Journal of Surgical Research, 185, 2, 2013. Crossref
-
Cho Edward I., Tan Chunrui, Koski Gary K., Cohen Peter A., Shu Suyu, Lee Walter T., Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines, Head & Neck, 32, 6, 2010. Crossref
-
Bobryshev Yuri V., Tran Dinh, Killingsworth Murray C., Buckland Michael, Lord Reginald V. N., Dendritic Cell-Associated Immune Inflammation of Cardiac Mucosa: A Possible Factor in the Formation of Barrett’s Esophagus, Journal of Gastrointestinal Surgery, 13, 3, 2009. Crossref
-
Koido Shigeo, Homma Sadamu, Hara Eiichi, Namiki Yoshihisa, Takahara Akitaka, Komita Hideo, Nagasaki Eijiro, Ito Masaki, Ohkusa Toshifumi, Gong Jianlin, Tajiri Hisao, Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions, Clinical and Developmental Immunology, 2010, 2010. Crossref
-
Kondoh H., Okano S., Yoshida K., Yonemitsu Y., Tomita Y., Yoshikai Y., Wake N., Sueishi K., Semi-Allogeneic Dendritic Cells Injected via the Intratumoural Injection Route Show Efficient Antitumour Effects in Cooperation with Host-Derived Professional Antigen-Presenting Cells, Scandinavian Journal of Immunology, 72, 6, 2010. Crossref
-
Koido Shigeo, Homma Sadamu, Hara Eiichi, Namiki Yoshihisa, Ohkusa Toshifumi, Gong Jianlin, Tajiri Hisao, Antigen-Specific Polyclonal Cytotoxic T Lymphocytes Induced by Fusions of Dendritic Cells and Tumor Cells, Journal of Biomedicine and Biotechnology, 2010, 2010. Crossref
-
Koido Shigeo, Homma Sadamu, Takahara Akitaka, Namiki Yoshihisa, Komita Hideo, Nagasaki Eijiro, Ito Masaki, Nagatsuma Keisuke, Uchiyama Kan, Satoh Kenichi, Ohkusa Toshifumi, Gong Jianlin, Tajiri Hisao, Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines, Journal of Biomedicine and Biotechnology, 2011, 2011. Crossref
-
Siders William M., Garron Carrie, Shields Jacqueline, Kaplan Johanne M., Induction of Antitumor Immunity by Semi-Allogeneic and Fully Allogeneic Electrofusion Products of Tumor Cells and Dendritic Cells, Clinical and Translational Science, 2, 1, 2009. Crossref
-
Dannull Jens, Tan Chunrui, Farrell Christine, Wang Cynthia, Pruitt Scott, Nair Smita K., Lee Walter T., Gene Expression Profile of Dendritic Cell-Tumor Cell Hybrids Determined by Microarrays and Its Implications for Cancer Immunotherapy, Journal of Immunology Research, 2015, 2015. Crossref
-
Eshel Rinat, Shpringer Meirav, Voskobinik Nadia, Vexler Akiva, Ben-Yosef Rami, Fabian Inna, Tartakovsky Boris, Naparstek Elizabeth, HLA-Identical Dendritic-Leukemic Cell Hybrids Generate Specific CTLs in Vitro, Journal of Cancer Therapy, 01, 03, 2010. Crossref
-
Hanlon Douglas J., Aldo Paulomi B., Devine Lesley, Alvero Ayesha B., Engberg Anna K., Edelson Richard, Mor Gil, Enhanced Stimulation of Anti-Ovarian Cancer CD8+ T Cells by Dendritic Cells Loaded with Nanoparticle Encapsulated Tumor Antigen, American Journal of Reproductive Immunology, 65, 6, 2011. Crossref
-
Pinho Mariana Pereira, Sundarasetty Bala Sai, Bergami-Santos Patricia Cruz, Steponavicius-Cruz Karen, Ferreira Adilson Kleber, Stripecke Renata, Barbuto José Alexandre M., Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells, Cytotherapy, 18, 4, 2016. Crossref
-
Zhang Yunfei, Luo Wen, Wang Yucai, Liu Yunyan, Zheng Lianhe, Mattei Fabrizio, Purified Dendritic Cell-Tumor Fusion Hybrids Supplemented with Non-Adherent Dendritic Cells Fraction Are Superior Activators of Antitumor Immunity, PLoS ONE, 9, 1, 2014. Crossref
-
Shurin Galina V., Tourkova Irina L., Kaneno Ramon, Shurin Michael R., Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism, The Journal of Immunology, 183, 1, 2009. Crossref
-
Lee Walter T., Dendritic Cell-Tumor Cell Fusion Vaccines, in Cell Fusion in Health and Disease, 713, 2011. Crossref
-
Gravante Gianpiero, Sconocchia Giuseppe, Ong Seok Ling, Dennison Ashley R., Lloyd David M., Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies, Liver International, 29, 1, 2009. Crossref
-
Lee Walter T., Shu Suyu, Role of Lymph Nodes in Immunotherapy of Malignant Tumors, in From Local Invasion to Metastatic Cancer, 2009. Crossref
-
Shurin Galina V., Amina Neil, Shurin Michael R., Cancer Therapy and Dendritic Cell Immunomodulation, in Dendritic Cells in Cancer, 2009. Crossref
-
Tanyi Janos L, Chu Christina S, Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review, Immunotherapy, 4, 10, 2012. Crossref
-
Chen Linghua, Zhang Xiaoyan, Primary analysis for clinical efficacy of immunotherapy in patients with pancreatic cancer, Immunotherapy, 8, 2, 2016. Crossref